Gylongiposide I
Based on 1 Customer Validation
Gylongiposide I is a selective inhibitor against the enterovirus EV71 with an EC50 of 1.53 μM. Gylongiposide I exerts antiviral activity by reducing viral protein VP1 expression and viral genomic RNA levels. Gylongiposide I can be used in the development of anti-EV71 drugs related to hand, foot and mouth disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.78%
- CAS. Nr.: 206876-12-2
- Formel: C46H76O16
- Molecular Weight:885.09
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biologische Aktivität
Beschreibung
IC50 & Target
|
EV71 |
Chemical Information
-
CAS. Nr. 206876-12-2
-
Appearance Solid
-
Molecular Weight 885.09
-
Formel C46H76O16
-
Color White to off-white
-
SMILES
O=C[C@@]12[C@]3([H])[C@]([C@]4([C@]([C@@](CC4)([H])[C@@](CO)(O)CC/C=C(C)\C)([H])CC3)C)(CC[C@@]1([H])C(C)([C@H](CC2)O[C@H]5[C@@H]([C@H]([C@H](CO5)O)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)O[C@H]7[C@@H]([C@@H]([C@H]([C@@H](O7)C)O)O)O)C)C
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Yin F, et al. Novel dammarane-type glycosides from Gynostemma pentaphyllum. Chem Pharm Bull (Tokyo). 2004 Dec;52(12):1440-4. [Content Brief]
[2]. Zhao H, et al. Enzymatic Biotransformation of Gypenoside XLIX into Gylongiposide I and Their Antiviral Roles against Enterovirus 71 In Vitro. Molecules. 2022 Jun 25;27(13):4094. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)